BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29343836)

  • 1. BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
    Amro Elshoury ; Wallace PK; Borowitz MJ; Kader A; Choi C; Ho C; Balderman S; Ross M; Hahn T; O'Neill V; McCarthy PL; Chen GL
    Bone Marrow Transplant; 2018 May; 53(5):651-653. PubMed ID: 29343836
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
    Ă˜bro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
    Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives and Future Directions for Acute Lymphoblastic Leukemia.
    Advani AS
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S6-9. PubMed ID: 27521327
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
    Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tisagenlecleucel (Kymriah) for ALL.
    Med Lett Drugs Ther; 2017 Oct; 59(1532):177-178. PubMed ID: 29039821
    [No Abstract]   [Full Text] [Related]  

  • 11. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
    Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2023 Mar; 43(1):115-125. PubMed ID: 36764804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial frequency of CD34+/CD38 - cells is not correlated with minimal residual disease level in 73 Chinese children with B-cell precursor acute lymphoblastic leukemia.
    Feng JH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Lymphoma; 2013 Sep; 54(9):2073-5. PubMed ID: 23323948
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
    Liu Z; Li Y; Shi C
    Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
    Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.
    Meyerson HJ; Blidaru G; Edinger A; Osei E; Schweitzer K; Fu P; Ho L
    Am J Clin Pathol; 2012 Jan; 137(1):39-50. PubMed ID: 22180477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.